Institute of General Practice and Family Medicine, Center of Health Sciences, Martin Luther University Halle Wittenberg, Halle (Saale), Germany.
Department of Preventive Medicine, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
Cochrane Database Syst Rev. 2023 Dec 12;12(12):CD008063. doi: 10.1002/14651858.CD008063.pub3.
Substance use is a global issue, with around 30 to 35 million individuals estimated to have a substance-use disorder. Motivational interviewing (MI) is a client-centred method that aims to strengthen a person's motivation and commitment to a specific goal by exploring their reasons for change and resolving ambivalence, in an atmosphere of acceptance and compassion. This review updates the 2011 version by Smedslund and colleagues.
To assess the effectiveness of motivational interviewing for substance use on the extent of substance use, readiness to change, and retention in treatment.
We searched 18 electronic databases, six websites, four mailing lists, and the reference lists of included studies and reviews. The last search dates were in February 2021 and November 2022.
We included randomised controlled trials with individuals using drugs, alcohol, or both. Interventions were MI or motivational enhancement therapy (MET), delivered individually and face to face. Eligible control interventions were no intervention, treatment as usual, assessment and feedback, or other active intervention.
We used standard methodological procedures expected by Cochrane, and assessed the certainty of evidence with GRADE. We conducted meta-analyses for the three outcomes (extent of substance use, readiness to change, retention in treatment) at four time points (post-intervention, short-, medium-, and long-term follow-up).
We included 93 studies with 22,776 participants. MI was delivered in one to nine sessions. Session durations varied, from as little as 10 minutes to as long as 148 minutes per session, across included studies. Study settings included inpatient and outpatient clinics, universities, army recruitment centres, veterans' health centres, and prisons. We judged 69 studies to be at high risk of bias in at least one domain and 24 studies to be at low or unclear risk. Comparing MI to no intervention revealed a small to moderate effect of MI in substance use post-intervention (standardised mean difference (SMD) 0.48, 95% confidence interval (CI) 0.07 to 0.89; I = 75%; 6 studies, 471 participants; low-certainty evidence). The effect was weaker at short-term follow-up (SMD 0.20, 95% CI 0.12 to 0.28; 19 studies, 3351 participants; very low-certainty evidence). This comparison revealed a difference in favour of MI at medium-term follow-up (SMD 0.12, 95% CI 0.05 to 0.20; 16 studies, 3137 participants; low-certainty evidence) and no difference at long-term follow-up (SMD 0.12, 95% CI -0.00 to 0.25; 9 studies, 1525 participants; very low-certainty evidence). There was no difference in readiness to change (SMD 0.05, 95% CI -0.11 to 0.22; 5 studies, 1495 participants; very low-certainty evidence). Retention in treatment was slightly higher with MI (SMD 0.26, 95% CI -0.00 to 0.52; 2 studies, 427 participants; very low-certainty evidence). Comparing MI to treatment as usual revealed a very small negative effect in substance use post-intervention (SMD -0.14, 95% CI -0.27 to -0.02; 5 studies, 976 participants; very low-certainty evidence). There was no difference at short-term follow-up (SMD 0.07, 95% CI -0.03 to 0.17; 14 studies, 3066 participants), a very small benefit of MI at medium-term follow-up (SMD 0.12, 95% CI 0.02 to 0.22; 9 studies, 1624 participants), and no difference at long-term follow-up (SMD 0.06, 95% CI -0.05 to 0.17; 8 studies, 1449 participants), all with low-certainty evidence. There was no difference in readiness to change (SMD 0.06, 95% CI -0.27 to 0.39; 2 studies, 150 participants) and retention in treatment (SMD -0.09, 95% CI -0.34 to 0.16; 5 studies, 1295 participants), both with very low-certainty evidence. Comparing MI to assessment and feedback revealed no difference in substance use at short-term follow-up (SMD 0.09, 95% CI -0.05 to 0.23; 7 studies, 854 participants; low-certainty evidence). A small benefit for MI was shown at medium-term (SMD 0.24, 95% CI 0.08 to 0.40; 6 studies, 688 participants) and long-term follow-up (SMD 0.24, 95% CI 0.07 to 0.41; 3 studies, 448 participants), both with moderate-certainty evidence. None of the studies in this comparison measured substance use at the post-intervention time point, readiness to change, and retention in treatment. Comparing MI to another active intervention revealed no difference in substance use at any follow-up time point, all with low-certainty evidence: post-intervention (SMD 0.07, 95% CI -0.15 to 0.29; 3 studies, 338 participants); short-term (SMD 0.05, 95% CI -0.03 to 0.13; 18 studies, 2795 participants); medium-term (SMD 0.08, 95% CI -0.01 to 0.17; 15 studies, 2352 participants); and long-term follow-up (SMD 0.03, 95% CI -0.07 to 0.13; 10 studies, 1908 participants). There was no difference in readiness to change (SMD 0.15, 95% CI -0.00 to 0.30; 5 studies, 988 participants; low-certainty evidence) and retention in treatment (SMD -0.04, 95% CI -0.23 to 0.14; 12 studies, 1945 participants; moderate-certainty evidence). We downgraded the certainty of evidence due to inconsistency, study limitations, publication bias, and imprecision.
AUTHORS' CONCLUSIONS: Motivational interviewing may reduce substance use compared with no intervention up to a short follow-up period. MI probably reduces substance use slightly compared with assessment and feedback over medium- and long-term periods. MI may make little to no difference to substance use compared to treatment as usual and another active intervention. It is unclear if MI has an effect on readiness to change and retention in treatment. The studies included in this review were heterogeneous in many respects, including the characteristics of participants, substance(s) used, and interventions. Given the widespread use of MI and the many studies examining MI, it is very important that counsellors adhere to and report quality conditions so that only studies in which the intervention implemented was actually MI are included in evidence syntheses and systematic reviews. Overall, we have moderate to no confidence in the evidence, which forces us to be careful about our conclusions. Consequently, future studies are likely to change the findings and conclusions of this review.
物质使用是一个全球性问题,据估计,约有 3000 万至 3500 万人存在物质使用障碍。动机性访谈(MI)是一种以客户为中心的方法,旨在通过探索他们改变的原因和解决矛盾心理,加强个人对特定目标的动机和承诺,从而在接受和同情的氛围中实现。这是对 Smedslund 及其同事 2011 年版本的更新。
评估 MI 对物质使用的有效性,即物质使用的程度、改变的意愿和治疗的保留率。
我们检索了 18 个电子数据库、6 个网站、4 个邮件列表以及纳入研究和综述的参考文献列表。最后一次检索日期是 2021 年 2 月和 2022 年 11 月。
我们纳入了使用药物、酒精或两者的个体的随机对照试验。干预措施是 MI 或动机增强治疗(MET),以面对面的方式单独进行。合格的对照干预措施是无干预、常规治疗、评估和反馈或其他积极的干预措施。
我们使用了 Cochrane 预期的标准方法程序,并使用 GRADE 评估证据的确定性。我们在四个时间点(干预后、短期、中期和长期随访)对三个结局(物质使用程度、改变的意愿和治疗的保留率)进行了荟萃分析。
我们纳入了 93 项研究,共计 22776 名参与者。MI 干预的持续时间从一次到九次不等。研究中包括住院和门诊诊所、大学、军队招募中心、退伍军人健康中心和监狱。我们判定 69 项研究在至少一个领域存在高偏倚风险,24 项研究存在低或不明确的偏倚风险。与无干预相比,MI 在干预后物质使用方面的效果较小至中等(标准化均数差(SMD)0.48,95%置信区间(CI)0.07 至 0.89;I = 75%;6 项研究,471 名参与者;低确定性证据)。在短期随访时,效果较弱(SMD 0.20,95% CI 0.12 至 0.28;19 项研究,3351 名参与者;非常低确定性证据)。这一比较显示,在中期随访时,MI 有获益的趋势(SMD 0.12,95% CI 0.05 至 0.20;16 项研究,3137 名参与者;低确定性证据),而在长期随访时则无差异(SMD 0.12,95% CI -0.00 至 0.25;9 项研究,1525 名参与者;非常低确定性证据)。在改变的意愿方面没有差异(SMD 0.05,95% CI -0.11 至 0.22;5 项研究,1495 名参与者;非常低确定性证据)。治疗保留率略高,MI 组(SMD 0.26,95% CI -0.00 至 0.52;2 项研究,427 名参与者;非常低确定性证据)。与常规治疗相比,MI 在干预后物质使用方面的效果较小至中等(SMD -0.14,95% CI -0.27 至 -0.02;5 项研究,976 名参与者;非常低确定性证据)。在短期随访时无差异(SMD 0.07,95% CI -0.03 至 0.17;14 项研究,3066 名参与者),在中期随访时 MI 有轻微获益(SMD 0.12,95% CI 0.02 至 0.22;9 项研究,1624 名参与者),在长期随访时则无差异(SMD 0.06,95% CI -0.05 至 0.17;8 项研究,1449 名参与者),均为低确定性证据。在改变的意愿方面没有差异(SMD 0.06,95% CI -0.27 至 0.39;2 项研究,150 名参与者),在治疗保留方面也没有差异(SMD -0.09,95% CI -0.34 至 0.16;5 项研究,1295 名参与者),均为非常低确定性证据。与评估和反馈相比,在短期随访时,物质使用方面无差异(SMD 0.09,95% CI -0.05 至 0.23;7 项研究,854 名参与者;低确定性证据)。在中期(SMD 0.24,95% CI 0.08 至 0.40;6 项研究,688 名参与者)和长期随访(SMD 0.24,95% CI 0.07 至 0.41;3 项研究,448 名参与者)时,MI 显示出轻微的获益,均为中等确定性证据。没有一项比较研究在干预后、改变意愿和治疗保留率方面测量物质使用情况。与另一种积极干预相比,在任何随访时间点,MI 在物质使用方面均无差异,均为低确定性证据:干预后(SMD 0.07,95% CI -0.15 至 0.29;3 项研究,338 名参与者);短期(SMD 0.05,95% CI -0.03 至 0.13;18 项研究,2795 名参与者);中期(SMD 0.08,95% CI -0.01 至 0.17;15 项研究,2352 名参与者);长期随访(SMD 0.03,95% CI -0.07 至 0.13;10 项研究,1908 名参与者)。在改变意愿方面没有差异(SMD 0.15,95% CI -0.00 至 0.30;5 项研究,988 名参与者;低确定性证据),治疗保留率(SMD -0.04,95% CI -0.23 至 0.14;12 项研究,1945 名参与者;中等确定性证据)也无差异。我们因不一致性、研究局限性、发表偏倚和不精确性而下调了证据的确定性。
动机性访谈可能会减少物质使用,与短期随访相比,无干预措施的效果更好。与评估和反馈相比,MI 可能会在中期和长期阶段轻微减少物质使用。与常规治疗和另一种积极干预相比,MI 对物质使用可能没有影响。尚不清楚 MI 是否会对改变意愿和治疗保留率产生影响。纳入的研究在许多方面存在差异,包括参与者的特征、使用的物质和干预措施。鉴于 MI 的广泛应用和研究数量众多,咨询师必须遵守并报告质量条件,以便只纳入真正实施 MI 的研究进行证据综合和系统评价,这一点非常重要。总的来说,我们对证据的信心是中等至高度的,这迫使我们谨慎对待我们的结论。因此,未来的研究很可能会改变本综述的发现和结论。